Key Drivers
- Strong Margins
- Ample Liquidity
- Lower Leverage
AIAI Summary
HRMY's low valuation reflects not weak execution but a concentrated WAKIX earnings stream facing 2030 exclusivity risk; investors should own it for its exceptional cash generation only if management can translate its $960M liquidity and pipeline into durable 2028–2032 revenue through disciplined deals and label expansions.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Margins
- •Ample Liquidity
- •Lower Leverage
HRMY shows strong profitability, liquidity, and improving margins, but rising valuation and investment-driven cash outflows warrant a selective stance.
Price Behavior
Key Price Behavior Insights:
- •Higher highs
- •Key resistance
- •Pullback risk
HRMY remains in a last-month uptrend above $40.81, but near-$42.74–$42.86 resistance and RSI near 66 favor watching for a breakout or a pullback toward $41.10–$41.50 support.
Recent pullback from $42.74 to $42.02 signals stalled breakout momentum
Sentiment & News
Key News Insights:
- •Share Price Gain
- •New Institutional Stake
- •EPX-100 Data
Harmony Biosciences gained momentum with a 12.1% post-earnings share rise, new institutional buying, and upcoming investor and epilepsy-data events.
The news flow is moderately positive, supporting investor interest while highlighting continued clinical-program catalysts
Similar Companies in Healthcare
Other companies in the same sector with AI ratings